Stock VVOS VIVOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-04-26 EDT 		5-day change 1st Jan Change
2.59 USD +5.28% Intraday chart for Vivos Therapeutics, Inc. -4.78% -79.18%
04-01 Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures MT
04-01 Top Premarket Decliners MT

Evolution of the average Target Price on Vivos Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4b6c042bcd9b0ca11f1fa.1HA-pRjcYgTm5dvMzX_VVdzNhcZxYODyLxbv6CTAWuQ.tSNq91rsG0iSkqKkuSWKbKaj9ZImVrnfWHuI2xTyLZ2ANUzyaa4zN46vrA~aad8bbb0814391ed5ef7156e39f381f0

Analyst Recommendations on Vivos Therapeutics, Inc.

Ascendiant Capital Starts Vivos Therapeutics at Buy With $2.50 Price Target MT
Roth Capital Lowers Price Target for Vivos Therapeutics to $8 From $9.75, Maintains Buy Rating MT
VIVOS THERAPEUTICS : Roth Capital Adjusts Price Target on to $11 From $12, Maintains Buy Rating MT
VIVOS THERAPEUTICS : Roth Capital Starts Vivos Therapeutics at Buy With $12 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.59 USD
Average target price
7.225 USD
Spread / Average Target
+178.96%
High Price Target
8.25 USD
Spread / Highest target
+218.53%
Low Price Target
6.2 USD
Spread / Lowest Target
+139.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vivos Therapeutics, Inc.

Ascendiant Capital
Roth Capital Partners

Ratings for Vivos Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VVOS Stock
  4. Consensus Vivos Therapeutics, Inc.